Mechanisms of Pulmonary Vascular Dysfunction in Heart Failure

Recruiting Observational Study
Heart Failure Pulmonary Hypertension Pulmonary Vascular Resistance Abnormality
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
230 (estimated)
Sponsor
Institute for Clinical and Experimental Medicine · Government
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Heart failure (HF) patients often develop pulmonary hypertension (PH) that leads to transition into a biventricular HF with poor prognosis. There are two PH components: 1) passive transmission of increased left atrial pressure, 2) heart failure (HF) related pulmonary vascular dysfunction (PVD) with increased vascular resistance. Intriguingly, only some, but not all HF patients develop heart failu…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
A) Inclusion Criteria HF group: * age\>18y * signed informed consent, * left ventricular (LV) ejection fraction \<50% * duration of HF\>6 months, * loop diuretic use, * clinical indication to right heart catheterisation Control group: * Age \>18years * Signed informed consent * Non-HF subjects r…
Contacts

Vojtech Melenovsky, MD, PhD

420 236055190

vome@ikem.cz

CONTACT